Tenvir 300 mg Cipla
| Features | |
| Active substance | Tenofovir |
| Also known as | TDF |
| Blood pressure | No significant effect |
| Chemical name | 9-[(R)-2-[[Bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]methoxy]propyl]adenine fumarate (1:1) |
| Dosage (medical) | 300 mg once daily |
| Dosage (sports) | Not applicable |
| Effects | Reduces the viral load in HIV-infected individuals, improves immune function |
| Formula | C19H30N5O10P В· C4H4O4 |
| Half-life | Approximately 17 hours |
| Hepatotoxicity | Low risk |
| Lab Test | Monitoring of renal function and bone density |
| Main action | Antiretroviral, inhibits HIV reverse transcriptase |
| Side effects | Nausea, vomiting, diarrhea, headache, dizziness, fatigue, renal impairment, bone loss |
| Storage conditions | Store at 20В°C to 25В°C (68В°F to 77В°F), excursions permitted between 15В°C to 30В°C (59В°F to 86В°F) |
| Substance class | Nucleotide reverse transcriptase inhibitor (NtRTI) |
| Trade name | Viread |
| Use in sports | None |
| Water Retention | No significant effect |
| Manufacturer | Cipla Ltd. |
| Packing | 30 tabs/bottle |